Non-GLP-1 alternatives Not every alternative needs to target incretin pathways
Another recently completed phase 3 clinical trial called REDEFINE 2 , which included 1,207 adults with type 2 diabetes and overweight or obesity, found that after 68 weeks, CagriSema led to weight loss of almost 16% experts say the highest yet in the type 2 population, compared to other weight management drugs like tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) and semaglutide
The myokine irisin increases cortical bone mass
Most manufacturers recommend using opened vials within 28 days when stored in a refrigerator at 2C to 8C (36F to 46F)
(Investing News Network (INN)) At the same time, pharmaceutical companies are actively developing next generation incretin therapies with improved efficacy profiles
A 2025 review of eight randomized trials found that moderate daily doses (620mg) were linked to higher HDL (good) cholesterol and lower triglyceride levels